NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Announces XLIF(R) Clinical Evidence at NASS and Initiates
Patent Infringement Lawsuit Against Globus Medical, Inc.

SAN DIEGO, CA, Oct 05, 2010 (MARKETWIRE via COMTEX) --

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that clinical evidence in support of XLIF(R) will be prominent at the NASS Meeting this year, which will take place from October 6th through October 8th, 2010, in Orlando, Florida. NuVasive will be the subject of numerous podium presentations, oral posters, and E-posters, and the Company will feature several surgeon-directed presentations at the NuVasive booth.

NuVasive also announced today that the Company initiated a patent infringement lawsuit against Globus Medical, Inc. The lawsuit contends that Globus Medical's LLIF(TM) lateral fusion offering (including instruments, implants and techniques sold under the trademarks TransContinental(R), MARS(R) 3V, and LLIF) infringes NuVasive's XLIF intellectual property.

Alex Lukianov, Chairman and Chief Executive Officer, said, "We very much look forward to another outstanding showing at NASS this year. Our technical exhibit will highlight the expanded applications and procedural differentiation that years of experience have afforded the XLIF(R) solution. The breadth of NuVasive's solutions to improve spine surgery will be palpable as our team of product specialists showcases a product portfolio that boasts over sixty-five innovative products. We take immense pride in our unique technology and the intellectual property rights that protect it and will aggressively use all offensive and defensive measures available to preserve the investments made to become the most creative spine technology company in the world. It is incumbent upon us as the pioneers of lateral surgery to protect the superior clinical outcomes XLIF has helped surgeons deliver to patients. NASS this year will be a true testament to the speed of innovation, superior clinical outcomes, and Absolute Responsiveness(R) that NuVasive offers to surgeons and hospitals."

XLIF(R) Podium Presentations

--  Changes in Coronal and Sagittal Plane Alignment after XLIF(R)
    Procedure in the Treatment of Degenerative Scoliosis
--  Extreme Lateral Interbody Fusion (XLIF(R)) for the Treatment of
    Degenerative Spondylolisthesis
--  XLIF(R) Retrieval Experience for Different Prostheses Models:
    Minimal Invasive Lateral Access for Success
--  The Subsidence Rate in XLIF(R) Osteoporotic Patients in Standalone
--  Evaluation of Hip Flexion Strength Following Extreme Lateral Lumbar
    Interbody Fusion: Is the Psoas Muscle Seriously Injured?
--  Outcomes of Minimally-Invasive Surgical Treatment (XLIF(R)) and the
    Role of Indirect Decompression on Neurologic Symptoms Relieve in Adult
    Deformity: Follow-up Out to 30 Months Post-Op
--  Economic Impact of Minimally Invasive Spine Surgery Open vs. MIS
    Spinal Fusion Costs in the Perioperative Period (First 45 Days)
--  Are MIS Spinal Fusion Outcomes Predictable? Factors of Statistically
    Significant Outcomes Predictability in Minimally Invasive Spinal

Other Podium Presentations Featuring NuVasive's Solutions

--  Meta-analysis of Class I and II Data on Results of Anterior Cervical
    Decompression and Fusion
--  Clinical and Radiographic Outcome of the NeoDisc Cervical Total Disc
    Replacement (TDR) at Two-Year Follow-up

Oral Posters

--  A Clinical Evaluation of Two-Level Lumbar Fusion Using a Combination
    of the AxiaLIF and XLIF(R)
--  Cervical Arthroplasty in Elderly: Prospective Six-Year Follow-up
--  Complications in 775 XLIF(R) Surgeries


--  Biomechanics of Disc Arthroplasty: What Can Be Done to Improve
    Results: Present and Future Perspectives
--  Changes in Coronal and Sagittal Plane Alignment after XLIF(R)
    Procedure in the Treatment of Degenerative Scoliosis
--  XLIF(R) Retrieval Experience for Different Prostheses Models:
    Minimal Invasive Lateral Access for Success
--  Lumbar Plexus Palsy after XLIF(R): An Avoidable Complication?
--  Outcomes of MIS Spinal Fusion: 12 and 24 Months
--  A Clinical Evaluation of Two-Level Lumbar Fusion Using a Combination
    of the AxiaLIF and XLIF(R)

NuVasive Booth #859 Presentations

--  XLIF(R) Corpectomy: Anterior column reconstruction without
    exposure-related morbidity; October 6th from 9:45 to 10:15 a.m. ET
--  MAS(R)-TLIF: Reproducible, pedicle-based, minimally disruptive
    surgery; October 6th from 12:00 to 1:00 p.m. ET and October 7th from
    10:00 to 10:30 a.m. ET
--  ILIF- Interlaminar Lumbar Instrumented Fusion: The new prescription
    for lumbar spinal stenosis; October 6th from 3:05 to 3:35 p.m. ET and
    October 8th from 12:00 to 1:00 p.m. ET
--  XLIF(R): Indication-specific treatment options; October 7th from
    12:00 to 1:00 p.m. ET
--  XLIF(R): Minimally invasive treatment of adult deformity; October
    7th from 3:30 to 4:00 p.m. ET
--  XLIF(R) Corpectomy through lateral approach; October 8th from 10:00
    to 10:30 a.m. ET

About NuVasive NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $5.1 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.7 billion global biologics market, the $1.7 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R)(R), NuVasive has built an entire spine franchise. With over 65 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
Email Contact

Patrick F. Williams
Vice President, Finance & Investor Relations
NuVasive, Inc.
Email Contact

Jason Rando
The Ruth Group
Email Contact

SOURCE: NuVasive, Inc.